IRDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Opus Genetics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$3.82−0.02 (-0.52%)
Close on Oct 19, 2026
- Market cap
- $425.49M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$1.95 (+104.3%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Opus Genetics, Inc. saw revenue fall 36.1% to $9.86M over the twelve months to Jun 30, 2026.
Revenue
$9.86M
-36.1% vs. a year earlier
Operating income
-$50.61M
TTM Q2 2026
EPS, diluted
-$1.35
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $425.49M
- P/E ratio
- –
- Price to sales
- 43.17
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $9.86M
- Net income
- -$107.61M
- EPS, diluted
- -$1.35
- Book value per share
- -$0.12
- Diluted shares
- 111M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$9.86M-36.1% YoY
Operating income
-$50.61M
Net income
-$107.61M
EPS, diluted
-$1.35
Free cash flow
–
Reported periodTrailing twelve months